Hemostemix's VesCell.Health Launched in Florida
Hemostemix (OTCQB: HMTXF) has launched VesCell.Health, an educational website in Florida to support the rollout of its VesCell鈩� autologous stem cell therapy. The launch follows Florida's SB 1768 legislation, which now allows the use of VesCell鈩� for patients with life-threatening conditions who have exhausted standard treatment options.
The website serves as an educational platform explaining the therapy's benefits and includes 11 peer-reviewed publications documenting VesCell's safety and efficacy across seven clinical trials. The therapy targets multiple conditions including peripheral arterial disease, chronic limb threatening ischemia, angina, and various forms of cardiomyopathy.
Hemostemix (OTCQB: HMTXF) ha lanciato VesCell.Health, un sito educativo in Florida a supporto del lancio della sua terapia con cellule staminali autologhe VesCell鈩�. Il lancio segue la legislazione della Florida, SB 1768, che ora consente l'uso di VesCell鈩� per pazienti con condizioni potenzialmente letali che hanno esaurito le opzioni terapeutiche standard.
Il sito funge da piattaforma informativa che spiega i benefici della terapia e include 11 pubblicazioni peer-reviewed che documentano la sicurezza e l'efficacia di VesCell in sette studi clinici. La terapia 猫 rivolta a diverse patologie, tra cui l'arteriopatia periferica, l'ischemia critica degli arti, l'angina e varie forme di cardiomiopatia.
Hemostemix (OTCQB: HMTXF) ha lanzado VesCell.Health, un sitio educativo en Florida para apoyar el despliegue de su terapia aut贸loga con c茅lulas madre VesCell鈩�. El lanzamiento sigue a la legislaci贸n de Florida, SB 1768, que ahora permite el uso de VesCell鈩� para pacientes con condiciones potencialmente mortales que han agotado las opciones de tratamiento est谩ndar.
El sitio funciona como una plataforma educativa que explica los beneficios de la terapia e incluye 11 publicaciones revisadas por pares que documentan la seguridad y eficacia de VesCell en siete ensayos cl铆nicos. La terapia aborda m煤ltiples afecciones, entre ellas la enfermedad arterial perif茅rica, la isquemia cr铆tica de las extremidades, la angina y varias formas de cardiomiopat铆a.
Hemostemix (OTCQB: HMTXF)電� 頂岆毽嫟鞐愳劀 鞛愱皜 欷勱赴靹疙彫 旃橂鞝� VesCell鈩㈧潣 霃勳瀰鞚� 歆�鞗愴晿旮� 鞙勴暣 甑愳湣鞖� 鞗轨偓鞚错姼 VesCell.Health毳� 臧滌劋頄堨姷雼堧嫟. 鞚措矆 於滌嫓電� 頂岆毽嫟鞚� 氩曥晥 SB 1768鞐� 霐半ジ 瓴冹溂搿�, 頃措嫻 氩曥晥鞚� 響滌 旃橂 氚╇矔鞚� 氇憪 鞁滊弰頃� 靸濍獏鞚� 鞙勴儨搿滌毚 頇橃瀽霌れ棎瓴� VesCell鈩� 靷毄鞚� 項堨毄頃╇媹雼�.
鞚� 鞗轨偓鞚错姼電� 旃橂鞚� 鞚挫爯鞚� 靹る獏頃橂姅 甑愳湣 頂岆灚韽检溂搿�, VesCell鞚� 鞎堨爠靹标臣 須姤鞚� 鞛呾頃橂姅 11韼胳潣 霃欕鞁偓 頃欖垹歆� 雲茧瓿� 7瓯挫潣 鞛勳儊鞁滍棙 瓴瓣臣毳� 韽暔頃橁碃 鞛堨姷雼堧嫟. 鞚� 旃橂氩曥潃 毵愳磮霃欕Д歆堩櫂, 毵岇劚 靷 甏挫偓靹� 項堩槇, 順戩嫭歃� 氚� 雼れ枒頃� 順曧儨鞚� 鞁芳氤戩 霌� 鞐煬 歆堩櫂鞚� 瓴儱頃╇媹雼�.
Hemostemix (OTCQB: HMTXF) a lanc茅 VesCell.Health, un site 茅ducatif en Floride pour soutenir le d茅ploiement de sa th茅rapie autologue par cellules souches VesCell鈩�. Ce lancement fait suite 脿 la loi de Floride SB 1768, qui autorise d茅sormais l鈥檜tilisation de VesCell鈩� pour les patients atteints de pathologies potentiellement mortelles ayant 茅puis茅 les options th茅rapeutiques standard.
Le site sert de plateforme p茅dagogique expliquant les b茅n茅fices de la th茅rapie et inclut 11 publications 茅valu茅es par des pairs documentant la s茅curit茅 et l鈥檈fficacit茅 de VesCell dans sept essais cliniques. La th茅rapie cible plusieurs affections, dont la maladie art茅rielle p茅riph茅rique, l鈥檌sch茅mie critique des membres, l鈥檃ngine et diverses formes de cardiomyopathie.
Hemostemix (OTCQB: HMTXF) hat VesCell.Health gestartet, eine Bildungswebsite in Florida zur Unterst眉tzung der Einf眉hrung seiner autologen Stammzelltherapie VesCell鈩�. Der Start folgt auf das Gesetz SB 1768 in Florida, das nun die Anwendung von VesCell鈩� bei Patienten mit lebensbedrohlichen Erkrankungen erlaubt, die alle Standardbehandlungen ausgesch枚pft haben.
Die Website dient als Informationsplattform, die die Vorteile der Therapie erkl盲rt, und enth盲lt 11 peer-reviewte Publikationen, die die Sicherheit und Wirksamkeit von VesCell in sieben klinischen Studien dokumentieren. Die Therapie zielt auf mehrere Erkrankungen ab, darunter periphere arterielle Verschlusskrankheit, chronische lebensbedrohliche Extremit盲tenisch盲mie, Angina und verschiedene Formen der Kardiomyopathie.
- Launch of educational platform increases therapy accessibility and awareness in Florida market
- Backed by 11 peer-reviewed publications and 7 clinical trials showing safety and efficacy
- Florida's SB 1768 legislation enables commercial use of VesCell for life-threatening conditions
- Limited to Florida market currently
- Treatment restricted to patients who have exhausted standard-of-care options
Calgary, Alberta--(Newsfile Corp. - September 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, today announces it launched in Florida, a dedicated educational website designed to help physicians and patients understand the benefits of VesCell™ , Hemostemix's groundbreaking autologous stem cell therapy.
Under physician order, following informed consent, Florida's law SB 1768 now permits the use of VesCell™ in patients with life-threatening or debilitating conditions who have exhausted standard-of-care treatment options.
VesCell.Health makes the science of using autologous (patient's own) stem cells understandable to the layman. The site presents complex clinical research in plain, accessible language, while also serving as a trusted repository of 11 peer-reviewed publications that document the safety and efficacy of VesCell across seven clinical trials, including a Phase II double blind randomized clinical trial in Critical Limb Threatening Ischemia (CLTI).
The site is structured to provide visitors with:
Clear, patient-friendly explanations of what VesCell is and how it works.
Evidence-based results from published clinical studies on conditions such as angina, ischemic cardiomyopathy, non ischemic cardiomyopathy, congestive heart failure, peripheral arterial disease, and chronic limb threatening ischemia.
Localized access for Florida residents, ensuring information is aligned with regional regulatory frameworks and treatment pathways.
"Launching VesCell.Health is about giving patients and their families the information they need, in words they can understand, supported by world-class science," said Thomas Smeenk, CEO of Hemostemix. "By combining plain language with peer-reviewed evidence, we are making the benefits of VesCell clear and approachable for physicians and Floridians who are searching for treatment answers and hope."
With the launch of VesCell.Health, Hemostemix continues its mission of advancing the understanding and accessibility of regenerative medicine while ensuring compliance within federal and state jurisdictional healthcare requirements.
ABOUT HEMOSTEMIX
Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). A recent peer-reviewed article in provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, and potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for , , , , , and . Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the . As compared to a five year mortality rate of
For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: [email protected] / PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to VesCell.Health in furtherance of the sales of VesCell™ (ACP-01), and the commercialization of ACP-01 via the sale and financing of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at . Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit
FAQ
What is VesCell.Health and when was it launched by Hemostemix (HMTXF)?
What conditions can be treated with Hemostemix's VesCell therapy?
How is VesCell therapy supported by clinical evidence?
Who is eligible for VesCell therapy under Florida's SB 1768?
Where can Florida residents access information about VesCell therapy?
